August 08, 2018
1 min read

FDA updates Mavyret label for new safety, efficacy data

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA recently approved safety and efficacy revisions to the Mavyret label based on data from a hepatitis C/HIV-1 collection study and a liver and renal transplant study.

Ongoing studies from the past year have shown Mavyret (glecaprevir/pibrentasvir, AbbVie) to be a pangenotypic treatment that is highly effective over an 8-week course for most patients.

According to the released revisions, the FDA recommends a 12-week course of glecaprevir/pibrentasvir for liver or kidney transplant recipients. The FDA also recommends a 16-week course for patients with genotype 1 and NS5A inhibitor-experienced without prior treatment with an NS3/4A protease inhibitor, and for patients with genotype 3 who are treatment-experienced with Sovaldi (sofosbuvir, Gilead Sciences) and ribavirin.

Regarding adverse reactions, results of two studies of patients with HCV/HIV-1 coinfection and genotypes 1, 2, 3, 4 or 6 showed a similar safety profile compared with HCV mono-infected patients. The FDA announced similar results from a study of patients treated post- liver and kidney transplant with genotypes 1, 2, 3, 4 or 6.

Among patients without cirrhosis or with compensated cirrhosis, both patients from the HCV/HIV-1 collection study and patients from the liver and renal transplant study demonstrated an overall sustained virologic response rate of 98%.